Format

Send to

Choose Destination
Mol Ther Methods Clin Dev. 2017 Oct 5;8:31-41. doi: 10.1016/j.omtm.2017.10.001. eCollection 2018 Mar 16.

Interactions between Retroviruses and the Host Cell Genome.

Author information

1
Genethon, 1bis rue de l'Internationale, 91002 Evry, France.
2
Department of Life Sciences, University of Modena and Reggio Emilia, 41125 Modena, Italy.

Abstract

Replication-defective retroviral vectors have been used for more than 25 years as a tool for efficient and stable insertion of therapeutic transgenes in human cells. Patients suffering from severe genetic diseases have been successfully treated by transplantation of autologous hematopoietic stem-progenitor cells (HSPCs) transduced with retroviral vectors, and the first of this class of therapies, Strimvelis, has recently received market authorization in Europe. Some clinical trials, however, resulted in severe adverse events caused by vector-induced proto-oncogene activation, which showed that retroviral vectors may retain a genotoxic potential associated to proviral integration in the human genome. The adverse events sparked a renewed interest in the biology of retroviruses, which led in a few years to a remarkable understanding of the molecular mechanisms underlying retroviral integration site selection within mammalian genomes. This review summarizes the current knowledge on retrovirus-host interactions at the genomic level, and the peculiar mechanisms by which different retroviruses, and their related gene transfer vectors, integrate in, and interact with, the human genome. This knowledge provides the basis for the development of safer and more efficacious retroviral vectors for human gene therapy.

KEYWORDS:

HIV; Moloney leukemia virus; gene therapy; histone modification; integration; integration site analysis; retroviruses; transcriptional regulation; viral tethering; viral vectors

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center